Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription 10.08.2026 1 AJR Am J Roentgenol 1 Br J Radiol 4 Eur Urol 3 Int J Urol 1 J Clin Oncol 1 J Magn Reson Imaging 2 J Nucl Med 3 J Urol 1 Nat Rev Urol 1 Oncogene 5 Prostate 1 Ther Adv Urol 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. PONSIGLIONE A, Brembilla G
   MRI Standards for Prostate Cancer Screening in the PRISM Consensus Recommendations.
   AJR Am J Roentgenol. 2026 Aug 5. doi: 10.2214/AJR.26.35683.
   PubMed        
   
   

   
   Br J Radiol

2. MICHALLEK F, Gordon S, Doran S, Ichikawa Y, et al
   Validation and diagnostic accuracy of Fractal Dimension as a biomarker for grading prostate cancer using data from clinical routine.
   Br J Radiol. 2026 Aug 7:tqag180. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Eur Urol

3. GUO C, Figueiredo I, Gurel B, Neeb A, et al
   Corrigendum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [European Urology 83 (2023) 224-238.
   Eur Urol. 2026 Aug 7:S0302-2838(26)02318-3. doi: 10.1016/j.eururo.2026.
   PubMed        
   
   
4. FROEHNER M
   Re: Armstrong AJ, Petrylak DP, Shore ND, et al. ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients. Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2025.12.02
   Eur Urol. 2026 Aug 7:S0302-2838(26)02161-5. doi: 10.1016/j.eururo.2026.
   PubMed        
   
   
5. GRISAY G, Turco F, Patrikidou A, Gallardo E, et al
   EORTC 2238 DE-ESCALATE: Revisiting Intermittent Maximal Androgen Blockade in Metastatic Hormone-sensitive Prostate Cancer.
   Eur Urol. 2026 Aug 5:S0302-2838(26)02286-4. doi: 10.1016/j.eururo.2026.
   PubMed         Abstract available
   
   
6. LUCA S, Ferrando L, Porpiglia F
   Re: Emanuele Messina, Antonella Borrelli, Alessandro Sciarra, et al. Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA). Eur Urol 2025;89:246-57.
   Eur Urol. 2026 Aug 4:S0302-2838(26)02218-9. doi: 10.1016/j.eururo.2026.
   PubMed        
   
   

   
   Int J Urol

7. FUJIWARA M, Fujikawa A, Aso S, Zaizen T, et al
   Transverse Versus Vertical Camera Port Incision for Patient Satisfaction After Robot-Assisted Radical Prostatectomy.
   Int J Urol. 2026;33:e70593.
   PubMed         Abstract available
   
   
8. YASUDA Y, Yoshida S, Yonese I, Sano Y, et al
   Real-World Outcomes of Olaparib Treatment in Japanese Patients With Metastatic Castration-Resistant Prostate Cancer Harboring BRCA Pathogenic or Likely Pathogenic Variants.
   Int J Urol. 2026;33:e70590.
   PubMed         Abstract available
   
   
9. ABE K, Miyazawa Y, Nakazawa S, Onose M, et al
   Real-World Outcomes of Radium-223 Therapy in Metastatic Castration-Resistant Prostate Cancer: Predictive Value of PSA Doubling Time and Enzalutamide Continuation.
   Int J Urol. 2026;33:e70591.
   PubMed         Abstract available
   
   

   
   J Clin Oncol

10. TAPLIN ME, Parikh RA, Rumble RB, Naqvi SAA, et al
    Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4.
    J Clin Oncol. 2026 Aug 6:101200JCO2601898. doi: 10.1200/JCO-26-01898.
    PubMed         Abstract available
    
    

    
    J Magn Reson Imaging

11. UMAPATHY L
    Editorial for "AI-Assisted Prostate Cancer Diagnosis Using Biparametric MRI and PI-RADS v2.1: Performance Comparison Between Novice-Level and Experienced Readers".
    J Magn Reson Imaging. 2026 Aug 7. doi: 10.1002/jmri.70473.
    PubMed        
    
    

    
    J Nucl Med

12. BAILLY C, Vija L, Somme F, Massard V, et al
    Real-World Outcomes of [(177)Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2026 Aug 6:jnumed.126.272721. doi: 10.2967/jnumed.126.272721.
    PubMed         Abstract available
    
    
13. CHAN JC, Carroll MT, Hitchen N, Hudson J, et al
    Thrombotic Microangiopathy in Patients Treated with (177)Lu-PSMA Combination Therapies.
    J Nucl Med. 2026;67:1254-1260.
    PubMed         Abstract available
    
    

    
    J Urol

14. LAZAROVICH A, Guer M, Luger F, Cash H, et al
    External Validation of the PRI-MUS Scoring System: A Secondary Analysis of the OPTIMUM Randomized Controlled Trial.
    J Urol. 2026;216:352-359.
    PubMed         Abstract available
    
    
15. NEGREAN C, Alam A, Biniam N, Salinas Miranda E, et al
    Postprostatectomy Urinary Continence Prediction: External Validation of a Model Incorporating MRI Derived Membranous Urethral Length.
    J Urol. 2026;216:360-368.
    PubMed         Abstract available
    
    
16. CALVO CI, Rourke KF
    Delineating the Long-Term Incidence of Urethral Complications After Prostate Cancer Treatment: A Population-Based Analysis.
    J Urol. 2026 Aug 7:101097JU0000000000005222. doi: 10.1097/JU.0000000000005222.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

17. CHESTNUT C, McKoy T, Westphalen AC, Lin DW, et al
    The clinical utility of prostate MRI before biopsy.
    Nat Rev Urol. 2026;23:542-550.
    PubMed         Abstract available
    
    

    
    Oncogene

18. HU J, Lai C, Xiao Y, Yan Z, et al
    Metabolic CRISPR screening identifies RPE as a key regulator of acquired enzalutamide resistance through FKBP5 destabilization in prostate cancer.
    Oncogene. 2026 Aug 3. doi: 10.1038/s41388-026-03946.
    PubMed         Abstract available
    
    

    
    Prostate

19. SCHALDEMOSE EL, Poulsen MH, Norby B, Madsen CV, et al
    Treatment of Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy.
    Prostate. 2026 Aug 2. doi: 10.1002/pros.70229.
    PubMed         Abstract available
    
    
20. SCHEIPNER L, Baudo A, Jannello LMI, Siech C, et al
    Comparisons of Novel Risk Stratification Models to the Current cT1a/b Staging in Incidental Prostate Cancer.
    Prostate. 2026 Aug 2. doi: 10.1002/pros.70221.
    PubMed         Abstract available
    
    
21. FUJIMOTO S, Morita T, Yamamoto Y, Inamoto T, et al
    Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
    Prostate. 2026 Aug 2. doi: 10.1002/pros.70230.
    PubMed         Abstract available
    
    
22. MCMASTER T, Louey CYM, Santucci J, Hobson C, et al
    Management of De Novo miN1 Prostate Cancer in the PSMA-PET Era.
    Prostate. 2026 Aug 2. doi: 10.1002/pros.70231.
    PubMed         Abstract available
    
    
23. SEKINE Y, Fujizuka Y, Nakazawa S, Tsuji Y, et al
    Predictive Value of [-2]proPSA-Related Indices for Prostate Cancer Detection Years Before Prostate-Specific Antigen Elevation: Insights From a Five-Year Longitudinal Screening Cohort.
    Prostate. 2026 Aug 2. doi: 10.1002/pros.70232.
    PubMed         Abstract available
    
    

    
    Ther Adv Urol

24. SKROBISZ K, Miszewski K, Marczak B, Miszewska L, et al
    Leveraging MRI to reduce overtreatment in low?grade prostate cancer: a retrospective single?centre cohort study.
    Ther Adv Urol. 2026;18:17562872261463095.
    PubMed         Abstract available
    
    

    
    Urology

25. KIM IE JR, Hartman R, Gandhi K, Nikita N, et al
    Mortality in Medicare-aged Men with Metastatic Prostate Cancer After the Introduction of Androgen Receptor Pathway Inhibitors: A Population-Based Study.
    Urology. 2026 Aug 4:S0090-4295(26)00491-7. doi: 10.1016/j.urology.2026.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum